Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Mirikizumab in Crohn's Disease
2019-002687-27Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Primary endpoint: Clinical remission by CDAI. Started Mar 2020; status: active.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-002687-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002687-27.